6-oxo-N-phenylhexanamide | 142326-25-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6-oxo-N-phenylhexanamide
• CAS: 142326-25-8
• 化学式: C₁₂H₁₅NO₂
• 分子量: 205.257
• InChiKey: SAFVBEYOKFUVGE-UHFFFAOYSA-N

物化性质

• 沸点：
  410.8±28.0 °C(Predicted)
• 密度：
  1.104±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-oxo-N-phenylhexanamide 在 吡啶 、 N-氯代丁二酰亚胺 、 盐酸羟胺 作用下， 以 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 18.5h， 生成 (Z)-6-(aziridin-1-yl)-6-(hydroxyimino)-N-phenylhexanamide
  参考文献：
  名称：

  Synthesis and biological evaluation of aziridin-1-yl oxime-based vorinostat analogs as anticancer agents

  摘要：

  The suberoyl anilide hydroxamic acid (vorinostat) analogs with the aziridin-1-yl oxime moiety as a possible metal chelating functionality have been synthesized. Their biological activity and stability under physiological conditions have been evaluated. Although some of the synthesized compounds demonstrated high antiproliferative activity against human HT1080 fibrosarcoma (HT1080, IC50 0.3-7.7 mu M) comparable to vorinostat (HT1080, IC50 2.4 mu M), they showed only weak histone deacetylase inhibition activity in HeLa cell line extracts.

  DOI：

  10.1007/s10593-015-1752-z
• 作为产物：
  描述：

  5-hydroxy-N-phenylpentanamide 在 pyridinium chlorochromate 作用下， 以 二氯甲烷 为溶剂， 生成 6-oxo-N-phenylhexanamide
  参考文献：
  名称：

  Synthesis and biological evaluation of aziridin-1-yl oxime-based vorinostat analogs as anticancer agents

  摘要：

  The suberoyl anilide hydroxamic acid (vorinostat) analogs with the aziridin-1-yl oxime moiety as a possible metal chelating functionality have been synthesized. Their biological activity and stability under physiological conditions have been evaluated. Although some of the synthesized compounds demonstrated high antiproliferative activity against human HT1080 fibrosarcoma (HT1080, IC50 0.3-7.7 mu M) comparable to vorinostat (HT1080, IC50 2.4 mu M), they showed only weak histone deacetylase inhibition activity in HeLa cell line extracts.

  DOI：

  10.1007/s10593-015-1752-z

文献信息

• Serotonin 5HT.sub.1A agonists
  申请人：Merrell Dow Pharmaceuticals Inc.

  公开号：US05189179A1

  公开（公告）日：1993-02-23

  The present invention is directed to a new class of serotonin 5HT.sub.1A agonists.

  本发明涉及一种新型的5HT.sub.1A受体激动剂。
• Synthesis of Dialkyl-Substituted Monofluoroalkenes via Palladium-Catalyzed Cross-Coupling of Alkyl Carbagermatranes
  作者：Chao Wang、Yu-Chao Liu、Meng-Yu Xu、Bin Xiao

  DOI：10.1021/acs.orglett.1c01289

  日期：2021.6.18

  An unprecedented cross-coupling reaction of alkyl carbagermatranes with bromofluoroolefins to deliver dialkyl-substituted monofluoroalkenes was achieved. This cross-coupling reaction was performed under base/additive-free conditions with excellent functional group tolerance, therefore offering an opportunity for challenging dialkyl-substituted monofluoroalkenes. The preparation of bioactive agent analogues

  实现了前所未有的烷基卡巴格马酯与溴氟烯烃的交叉偶联反应，以提供二烷基取代的单氟烯烃。这种交叉偶联反应在无碱/无添加剂的条件下进行，具有优异的官能团耐受性，因此为挑战二烷基取代的单氟烯烃提供了机会。包括抗结核剂模拟物和 COX-2 抑制剂类似物在内的生物活性剂类似物的制备以及药物分子衍生物的后期氟烯基化证明了该策略的实用性。
• GEMCITABINE PRODRUGS AND USES THEREOF
  申请人：BoYen Therapeutics, Inc.

  公开号：US20140134160A1

  公开（公告）日：2014-05-15

  The present invention provides compounds according to formula I: and pharmaceutically acceptable salts thereof. For compounds of formula I, R 1 and R 2 are independently selected from the group consisting of H, —C(═O)—(CH 2 ) 2 -aryl, and —C(═O)—(CH 2 ) n —C(═O)—NH-aryl. The subscript n is from 2 to 6. R 3 is selected from the group consisting of H and —C(═O)—O—R 4 ; and R 4 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, arylalkyl, substituted arylalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl and substituted heteroalkyl. Compounds are provided wherein at least one of R 1 and R 2 is other than H. Pharmaceutical compositions, methods for inhibiting the growth of cancer cells, and methods for the treatment of cancer are also provided.

  本发明提供了公式I的化合物及其药学上可接受的盐。对于公式I的化合物，R1和R2独立地选择自H，—C（═O）—（CH2）2-芳基和—C（═O）—（CH2）n—C（═O）—NH-芳基的群组。下标n为2至6。R3选择自H和—C（═O）—O—R4的群组；而R4选择自烷基，取代烷基，烯基，取代烯基，炔基，取代炔基，芳基烷基，取代芳基烷基，环杂芳基烷基，取代环杂芳基烷基，杂基和取代杂基的群组。提供了至少一个R1和R2不是H的化合物。还提供了制药组合物，抑制癌细胞生长的方法和治疗癌症的方法。
• Serotonin 5HT1A and 5HT1D antagonists
  申请人：MERRELL PHARMACEUTICALS INC.

  公开号：EP0478954A1

  公开（公告）日：1992-04-08

  The present invention is directed to a new class of serotonin 5HT1A agonists and pharmaceutical compositions containing them.

  本发明涉及一类新的血清素 5HT1A 激动剂和含有它们的药物组合物。
• Serotonin 5HT1A and 5HT1D agonists
  申请人：MERRELL PHARMACEUTICALS INC.

  公开号：EP0478954B1

  公开（公告）日：2000-10-18